Autologous whole-cell cancer vaccination: Cryogenic silicified vaccines

Abstract

Autologous whole-cell cancer vaccines represent one of the most important medical achievements. While their development has been historically fraught with difficulty, their clinical efficacy remains modest. In a recent paper published in <i>Nature Biomedical Engineering</i>, Guo et al. reported a new modular cryogenic silicified cancer vaccine capable of binding pathogen-associated molecular patterns to elicit protective and therapeutic efficacy for personalized immune therapy. This strategy also promises the benefit of long-term storage without loss of efficacy after dehydration and rehydration and can be potentially adapted to multiple tumor types.